Neuland Laboratories Ltd Stock Analysis

BSE: 524558 | NSE: NEULANDLAB | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 26-Sep-2022 18:01
1353.00 -22.95 (-1.67%)

DeciZen - Make an Informed Decision on Neuland Laboratories

Overall Rating

1. Quality

2. Valuation

Fair

3. Price Trend

Neuland Laboratories Price Chart

P/E Ratio (SA) :
27.27
Market Cap :
1,765.3 Cr.
52-wk low :
965.9
52-wk high :
1,875
Bole Toh?

1. Is Neuland Laboratories Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Neuland Laboratories Ltd is a below average quality company.

2. Is Neuland Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Neuland Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Neuland Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Neuland Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Neuland Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Neuland Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 12.3%14.9%10.8%12.1%11.2%3.2%3.4%3.4%8.9%7.4%-
Value Creation Index -0.10.1-0.2-0.1-0.2-0.8-0.8-0.8-0.4-0.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 461466469510579527667763937951971
YoY Gr. Rt. %-1.1%0.7%8.7%13.5%-8.9%26.4%14.4%22.8%1.5%-
Adj EPS 1936.518.529.353.113.815.513.156.850.650.5
YoY Gr. Rt. %-92.3%-49.2%58.1%81%-73.9%11.9%-15.5%334%-10.9%-
BVPS (₹) 121.8151.8179206.3260273.5541.5549.2608.7650.6658.2
Adj Net Profit 15.229.316.526.147.212.319.916.872.864.965
Cash Flow from Ops. 26.248.513.144.738.911.569.656.618958.6-
Debt/CF from Ops. 8.13.914.44.14.927.73.34.60.93.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.4%10.4%12.6%1.5%
Adj EPS 11.5%-1%48.4%-10.9%
BVPS 20.520.16.36.9
Share Price 26.5% 5.9% 40.1% -12%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 17.526.511.715.1132.23.22.49.887.7
Op. Profit Mgn % 13.215.914.415.718.59.69.513.515.915.214.7
Net Profit Mgn % 3.36.33.55.18.22.332.27.86.86.7
Debt to Equity 2.21.61.210.81.30.30.40.20.3-
Working Cap Days 1872112442332202842422252072180
Cash Conv. Cycle 607382871061521211161061240

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 7.70%

Sales growth is growing at healthy rate in last 3 years 12.56%

Net Profit is growing at healthy rate in last 3 years 48.37%

Sales growth is not so good in last 4 quarters at 4.46%

Latest Financials - Neuland Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 50.5 50.7
TTM Sales (₹ Cr.) 971 971
BVPS (₹.) 658.2 662.2
Reserves (₹ Cr.) 832 837
P/BV 2.09 2.08
PE 27.27 27.14
From the Market
52 Week Low / High (₹) 965.85 / 1875.00
All Time Low / High (₹) 14.26 / 2840.00
Market Cap (₹ Cr.) 1,765
Equity (₹ Cr.) 12.8
Face Value (₹) 10
Industry PE 37.9

Management X-Ray of Neuland Laboratories :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *4.314.304.304.304.304.304.304.300.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Neuland Laboratories

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

About Neuland Laboratories Ltd

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.

Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.

The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.

Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Product range of the company includes:

  • Anti -Asthmatics
  • Fluoroquinolones
  • Cardiovascular
  • CNS
  • Corticosteroids
  • Anti-Ulcerant
  • Anti-Fungal
  • Anti-Parkinsons
  • Anti-Alzheimers

Achievements/ recognition:

  • Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
  • USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
  • Received cGMP clearance for both facilities from TGA, Australia in 2004.
  • Certificate of suitability for product itraconazole in 2006.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now